SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " drug " 1,591 found 🔀 AI-powered Shuffle
Trump officials propose new requirements for food additives and ingredients
U.S. health officials want food manufacturers to provide more information about new additives and ingredients. Under a proposal announced Monday, food companies would have to notify the Food and Drug
Funding Science for the Long Term: The Role of Private Philanthropy
A drug that reaches a pharmacy shelf today often rests on discoveries made decades earlier. Yet the institutions financing scientific research do not
US health agency moves to increase oversight of food additives
The U.S. Food and Drug Administration on Monday took steps to increase oversight of food additives as part of the Trump administration's "Make America Healthy Again" initiative.
Chrissy Metz Talks '& Juliet' and New Music, Shares Health Update
Chrissy Metz, “This is Us” and “The Hunting Wives” star, joins TODAY to open up for the first time about her decision to use GLP-1 medication and announce her new partnership with health care company Ro. Metz details why she was originally skeptical around weight loss drugs, shares how the medication has improved her life, dishes on performing in “& Juliet” and teases new music in the works.
AbCellera women’s health data top ‘most aggressive upside scenario,’ putting Astellas and Bayer on notice
AbCellera has reported phase 2 results “beyond even the most aggressive upside scenario” that its CEO dared to consider, boosting the biotech’s chances of challenging Astellas and Bayer for a women’s health market. The phase 2 clinical trial compared ABCL635, an antibody targeting NK3R, to placebo in patients with hot flashes caused by menopause. Investigators enrolled 92 postmenopausal women experiencing a mean of about 10 moderate or severe hot flashes per day. By Week 4, the number of moderate or severe hot flashes had fallen by a mean of 8.8 on ABCL635 and by 3.5 on placebo. That statistically significant, placebo-adjusted reduction of 5.3 hit the trial’s primary endpoint. The level of efficacy also cleared the bar set by existing drugs. While cross-trial comparisons can be misleading, AbCellera CEO Carl Hansen, Ph.D., had seen enough to start hyping the program. “We now view ABCL635 as a potential best-in-class non-hormonal therapy with strong differentiation against approved NK3R competitors across all important dimensions, including efficacy, safety, dosing and convenience,” Hansen said on a Monday morning conference call with investors to discuss the data. “We believe ABCL635 is now a highly de-risked program.” Last week, Hansen used AbCellera’s earnings call to set expectations for readout, with the CEO defining success as a clean safety profile and efficacy comparable to the two approved small molecules. The data vaulted over that bar. Astellas linked (PDF) one of the small molecules, Veozah, to placebo-adjusted reductions in hot flash frequency of 2.1 and 2.6 at Week 4 of its two phase 3 trials. Bayer reported (PDF) placebo-adjusted reductions of 3.04 and 3.29 at Week 4 of pivotal studies for its small molecule, Lynkuet. At 5.3, the placebo-adjusted reduction in AbCellera’s trial comfortably cleared the standard set by the incumbents. Veozah and Lynkuet came to market based on evidence of their ability to reduce the frequency and severity of hot flashes. AbCellera’s phase 2 study covered both endpoints, with the Canadian biotech reporting a mean reduction in severity of 1.4 points at Week 4 on ABCL635, compared to 0.3 points for placebo. Again, the placebo-adjusted result compares favorably to data on Veozah and Lynkuet. Analysts shared Hansen’s enthusiasm for the data. The phase 2 results “firmly validate ABCL635 as a potentially best-in-class treatment,” BMO Capital Markets analysts said in a note to investors Monday. ABCL635’s apparent efficacy edge “is likely attributable to the higher dosing/target engagement the asset is able to reach vs. the oral agents due to its wider therapeutic index,” the analysts added. The analysts, who model $2.3 billion in unadjusted peak sales for ABCL635, flagged the safety profile as another positive of the phase 2 readout. While Veozah carries a boxed warning for liver damage, nobody on ABCL635 in the phase 2 trial had elevated liver enzymes or bilirubin values. If replicated in phase 3, the lack of a liver signal could allow approval without the monitoring requirements imposed on Veozah. Investors appeared equally enthused, sending AbCellera's stock up 32% to $9.21 in premarket trading Monday from a Friday closing price of $6.93. Next, AbCellera will collect the Week 12 data and talk to its advisors about further development. The results open up “a wide variety of possibilities of how we might take this forward into phase 3 studies to truly maximize the value of the asset and make sure that ABCL635 is able to demonstrate its differentiation potential,” Sarah Noonberg, M.D., Ph.D., AbCellera’s chief medical officer, told investors.
Chrissy Metz Reveals She’s Taking a GLP-1 Drug: EXCLUSIVE
The actor discussed the mental and physical changes she’s noticed since partnering with Ro.
Kylo Peptides Expands Research Catalog to 36 Compounds as Peptide Science Enters a Record Growth Cycle
US research-peptide supplier scales its catalog against a market that analysts value between $47 billion and $141 billion, as peptides hold near 10% of new FDA drug approvals and GLP-1 use among American adults doubles in 18 months.Sheridan, Wyoming, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Kylo Peptides, a US supplier of research-grade peptides, has expanded its catalog to around 36 peptides and research blends, the company announced today. The milestone lands during the most active growth period in t
The Lancet Regional Health – Europe: Europe’s failure to deliver on drug-resistant TB
The Europe's TB paradox: some of the world's wealthiest and most advanced health systems are failing to implement known tools to tackle drug-resistant TB.
Public health alert issued for meat and poultry products containing recalled jalapeños
The U.S. Department of Agriculture’s Food Safety and Inspection Service is issuing a public health alert for meat and poultry products containing Food and Drug Administration-regulated jalapeños that may be contaminated with Salmonella.
Public health alert issued for meat and poultry products containing recalled jalapeños
The U.S. Department of Agriculture’s Food Safety and Inspection Service is issuing a public health alert for meat and poultry products containing Food and Drug Administration-regulated jalapeños that may be contaminated with Salmonella.
Public health alert issued for meat and poultry products containing recalled jalapeños
The U.S. Department of Agriculture’s Food Safety and Inspection Service is issuing a public health alert for meat and poultry products containing Food and Drug Administration-regulated jalapeños that may be contaminated with Salmonella.
Public health alert issued for meat and poultry products containing recalled jalapeños
The U.S. Department of Agriculture’s Food Safety and Inspection Service is issuing a public health alert for meat and poultry products containing Food and Drug Administration-regulated jalapeños that may be contaminated with Salmonella.
Public health alert issued for meat and poultry products containing recalled jalapeños
The U.S. Department of Agriculture’s Food Safety and Inspection Service is issuing a public health alert for meat and poultry products containing Food and Drug Administration-regulated jalapeños that may be contaminated with Salmonella.
Public health alert issued for meat and poultry products containing recalled jalapeños
The U.S. Department of Agriculture’s Food Safety and Inspection Service is issuing a public health alert for meat and poultry products containing Food and Drug Administration-regulated jalapeños that may be contaminated with Salmonella.
Public health alert issued for meat and poultry products containing recalled jalapeños
The U.S. Department of Agriculture’s Food Safety and Inspection Service is issuing a public health alert for meat and poultry products containing Food and Drug Administration-regulated jalapeños that may be contaminated with Salmonella.
What are Zyn nicotine pouches and are they safe?
The Food and Drug Administration is allowing the company Zyn to advertise some of its nicotine pouches as safer in some ways than smoking cigarettes.
Overcrowding, drugs and health crisis behind Mecklenburg jail deaths, sheriff says
Recent deaths spark state investigations as leaders remain split on reopening Jail North
On Sugar Ray, Pavement and \'90s music nostalgia in 2026 [Unscripted]
Nostalgia, and our relationship with it, is a funny thing. It’s a potent drug that makes the hazy feel distinct and something clear seem warped. I recently saw two bands
Drug-resistant fungas on the radar in Michigan as health experts monitor spread
The fungus can live on surfaces, move from person to person and, in some cases, resist the drugs used to treat it. For people who are already sick, the fungus can become life-threatening and, in some cases, fatal.
Vitamin C may fight cancer — but not the way scientists once thought
Linus Pauling was widely mocked for claiming that vitamin C could fight cancer, especially after trials using vitamin C pills showed no benefit. Researchers now know that intravenous vitamin C reaches vastly higher concentrations and can behave more like an experimental cancer drug than an ordinary supplement. Early studies suggest it may damage vulnerable cancer cells, reduce treatment side effects, and possibly improve outcomes for some patients.
Everyone's talking about hormone therapy for menopause. Should I be on it?
For years doctors advised women against hormone therapy for women in the menopausal transition. Now everyone's talking about how great it is. Is it really a wonder drug that women should all be on?
New Orleans Saints Rookie Wide Receiver and Son of WWE Star Suspended 6 Games
New Orleans Saints rookie wide receiver Brock Rechsteiner catches a six game suspension from the NFL league office. While the current reason for the suspension in unknown, suspensions for performance enhancing drugs start at four games. They increase to six games when there is an attempted manipulation. Brock Rechsteiner has been suspended by the Commissioner […] The post New Orleans Saints Rookie Wide Receiver and Son of WWE Star Suspended 6 Games appeared first on HEAVY.
Wearable ultrasound patch boosts REM sleep without drugs or surgery
A new wearable patch may help people reach REM sleep faster and remain there longer without medication or surgery. In a study of 28 participants, the device shortened the time to REM by 43 minutes and extended it by about 16 minutes. Researchers also observed signs of improved stress regulation and changes in brain circuits tied to emotion.
New heart drug targeting inflammation falls short in clinical trial
The ZEUS trial fell short, but Novo Nordisk still has high hopes for HERMES and ARTEMIS.
Xeris raises outlook despite posting $31.1 million loss
Executives argue the loss reflects a one-time accounting charge to clear outstanding debt rather than the drugmaker's performance.
A Promising Heart Drug Fails, Challenging a Long-Held Theory of Disease
The drug targeted inflammation, and its shocking failure has experts questioning whether inflammation really does cause heart disease.
Merck KGaA raises profit guidance on momentum in Life Science, Electronics units
Germany's Merck KGaA lifted its earnings guidance range for 2026 on Thursday, citing a further gain in demand for its drug manufacturing supplies and semiconductor materials, while posting better-than-expected quarterly results.
FDA approves first mRNA-based flu vaccine
The US Food and Drug Administration on Wednesday approved the United States’ first mRNA-based flu vaccine for adults 50 and older, drugmaker Moderna said.
Wisconsin pharmacist says Trump’s tariffs could end his business
The owner of Fitchburg Family Pharmacy says his pharmacy could close due to Trump’s tariffs on generic drugs.
Sanofi suspends chronic lung disease phase 2 study, tied to ‘strategic business reasons’
Sanofi halted a phase 2 trial testing a monoclonal antibody, SAR445399, in non-cystic fibrosis bronchiectasis, Fierce Biotech has learned. The trial, which began only back in April, was a randomized, double-blind, placebo-controlled study to measure the reduction in mucus plug score following treatment with SAR445399 compared with placebo in adults aged 18 to 80 years with NCFB, a chronic lung disease. The trial was officially reported as halted on July 29, the day before Sanofi’s second-quarter earnings call. The decision to pause the trial was made “as part of a company-wide portfolio review for strategic business reasons,” and not due to safety concerns, a Sanofi spokesperson told Fierce. The move to pause the NCFB trial comes during a trying time for Sanofi following a year filled with a series of trial fails. In February, the French pharma ousted CEO Paul Hudson and appointed Merck KGaA leader Belén Garijo, M.D., Ph.D., to steer the ship. Since then, Garijo has been doing a deep dive on correcting the company’s strewn R&D and clinical strategies. On July 24, Sanofi scrapped amlitelimab for atopic dermatitis, despite its lore as being a potential $5 billion blockbuster. During its second-quarter report, the company abandoned two more assets, balinatunfib and itepekimab, following failed trial results in psoriasis and chronic obstructive pulmonary disease, respectively. SAR445399, only first revealed by Sanofi in 2023, is an anti-interleukin-1 receptor 3 monoclonal antibody developed to block the interleukin 1, 33, and 36 cytokine pathways. These pathways can be important in chronic immune-related dermatologic diseases, such as atopic dermatitis and hidradenitis suppurativa, as well as respiratory conditions, such as NCFB. Related Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues NCFB affects roughly half a million people in the U.S., with a global incidence of greater than one million cases. In August 2025, Insmed received FDA approval for Brinsupri, a DPP1 inhibitor targeting neutrophil activation, for treatment of NCFB in adults and kids ages 12 and older. The British biotech Infex Therapeutics showed promising NCFB phase 2a data using their monoclonal antibody, INFEX702, which acts by disabling Pseudomonas aeruginosa, a bacteria known to be a major pathogen of NCFB. Sanofi is currently running a separate phase 2 study testing SAR445399 as a potential treatment for the inflammatory skin condition hidradenitis suppurativa.
Why AI Still Hasn't Had Its Einstein Moment
AI is having a remarkable run in science. It’s helping researchers predict protein structures, improve weather forecasts, discover new materials, and speed up drug discovery. Researchers are getting results far […]
NSF Presents Highest Award to H-SC Professor
The National Science Foundation (NSF) has awarded its most prestigious grant to Elliott Professor of Chemistry Timothy M. Reichart for his work in drug discovery, chemical protein synthesis, and educational methods that advance the sciences.
AI finds previously undetected health risks during sleep studies
We also report on another promising experimental non-opioid pain drug for use following surgery.
The Beauty Of Settled Science
Commenters convinced me I made a subtle mis-step in my framing of Psychology Research Is Mostly Fine. My framing emphasized that social priming studies had failed to replicate, but that many other subfields of psychology hadn’t. This naturally led commenters to point to failed replications in other subfields. Although none of these were as bad as social priming, few or none were entirely problem-free. Instead of emphasizing the difference between social priming and other subfields, I should have emphasized the difference between settled science and novel research. Here are some of my favorite psychology findings: The brain is sculpted by reinforcement learning, and a key driver of this learning is a prediction-error-based algorithm located in the nucleus accumbens and implemented through dopamine. Psychedelic drugs exert their effects through 5-HT2A receptors, pointing to a role for these receptors in some sort of construct like the balance between priors and new evidence. Certain cognitive functions are localized to certain brain areas (for example, impulse control to the frontal lobes; linguistic structure to Broca’s area, linguistic meaning to Wernicke’s area. But injure one of these areas, or render a certain function useless (eg a blind person having no more use for their visual cortex), and these mappings can gradually shift - suggesting that neurons are general-purpose compute whose specialization is a contingent fact about convenience and efficiency rather than a necessity. Most personality traits and general capabilities are about 50% genetic and 50% random, with little role for family environment or childhood history, with a few notable exceptions like partisan preference. Recent research complicates this story, but the further you go from this basic picture, the gnarlier the chains of indirect causation you require. Neurons fire together in “brain waves”, whose exact frequency corresponds with the character of consciousness; These divide neurons into natural subpopulations and linked graphs. The gamma rhythm corresponds surprisingly well to items in conscious awareness. GABA receptors seem to be involved in something like relaxation. By hitting different GABA receptors in different ways, you can modulate the exact type of relaxation you produce. Hitting GABA-A directly is too powerful and can cause dangerous levels of sedation, but allosteric modulation of GABA is an incredibly fruitful strategy that underlies drugs from benzos to barbituates to alcohol. If you know your GABA-A subunits, you can target specific subtypes of relaxation; for example, Ambien hits GABA-A1 and induces sleep. Memory divides somewhat fuzzily into bins of immediate-sensory, short-term, and long-term, with separate retrieval and storage functions, and separate systems for declarative vs. procedural learning. These can be harmed selectively, usually by hippocampal injury, so that some patients can remember their life stories but not form new long-term memories, or learn new skills like bike-riding but not new facts. The exact substrate of memory is unclear but seems to involve new synaptic connections between neurons in at least some way. The ability of modern psychology and psychiatry to treat mental illness is real but limited. SSRIs work for half or slightly fewer than half of patients; antipsychotics work with extreme side effects; benzodiazpines work but produce addiction and tolerance in many (not all) people. Most supplements are stuck in Poor Quality Study Replication Crisis Hell, but melatonin and l-theanine stand out as especially promising. Psychotherapy works with moderate effect size, but (with a few exceptions) seems to be more about the relationship with the provider than the details of the therapy itself. Mental hospitalization can sometimes defuse immediate crises but work less well than mental hospitals would like, with some studies showing overall negative effects. Schizophrenia is mostly genetic, but risk also increases with prenatal infection (especially rubella) and obstetric complications; there is suggestive evidence for roles of social stress and drug use (with psychedelics and marijuana making things worse, and nicotine if anything making things better). Bipolar and schizophrenia are so closely linked on a pathophysiological level that it seems like they might be the same disease; on the clinical level, they do seem to follow two separate courses/prognoses but can sometimes surprise clinicians by eg someone who seemed condemned to permanent schizophrenia unexpectedly recovering. The brain’s native reinforcement learning algorithms cash out in the phenomena of classical and operant conditioning; different reinforcement schedules reinforce at different levels, which can be exploited by bad actors to make especially compelling products (eg slot machines). None of these are immune to doubt. A few are speculative; one or two are genuinely unorthodox. But they’re all a step above one p = 0.049 paper that might not replicate. If they get overturned, they’ll be overturned by the same sort of genuine scientific shift that replaced Ptolemy with Copernicus or Lamarck with Darwin, not some sort of sordid discovery about someone entering random numbers into a spreadsheet. In 2008, Eliezer Yudkowsky wrote about The Beauty Of Settled Science: If you only care about scientific issues that are controversial, you will end up with a head stuffed full of garbage. The media thinks that only the cutting edge of science is worth reporting on. How often do you see headlines like “General Relativity still governing planetary orbits” or “Phlogiston theory remains false”? So, by the time anything is solid science, it is no longer a breaking headline. “Newsworthy” science is often based on the thinnest of evidence and wrong half the time—if it were not on the uttermost fringes of the scientific frontier, it would not be breaking news. Scientific controversies are problems so difficult that even people who’ve spent years mastering the field can still fool themselves. That’s what makes for the heated arguments that attract all the media attention. Worse, if you aren’t in the field and part of the game, controversies aren’t even fun. Don’t be embarrassed to read elementary science textbooks, either. If you want to pretend to be sophisticated, go find a play to sneer at. If you just want to have fun, remember that simplicity is at the core of scientific beauty [...] A steady diet of science news is bad for you: You are what you eat, and if you eat only science reporting on fluid situations, without a solid textbook now and then, your brain will turn to liquid. Psychology isn’t centrally the new paper in Annals Of Recently-Breaking News saying that an n=5 study showing that large portion sizes increase support for terrorism. Psychology is centrally ideas like brain waves, GABA receptors, reinforcement learning, twin studies, and connectionism. People who think differently are worrying too much about BREAKING NEWS!!!, and should stop. The key distinction isn’t “recent research in social psychology” vs. “recent research in cognitive/bio/behavioral psychology”, as my essay last week unfortunately implied. It’s recent research in general vs. the deposit of settled science, battle-tested hypotheses, and carefully-earmarked speculation. And part of the reason social priming in particular was such a disaster was that it defied that heuristic, building itself up over hundreds of studies until it approached or even entered the pantheon of settled science - before collapsing (5-HTTLPR was also sort of like this). This isn’t a claim that settled science is always right - Freud was “settled science” for a long time - just that there’s an intuitive distinction between the level of credence you should have in the existence of power posing vs. the existence of Broca’s Area. (I compounded this error by calling the last post “Psychology Research Is Mostly Fine”, which suggested I was talking about the new research rather than the settled science. I actually meant to distinguish between research-psychology-the-field vs. clinical-psychology-aka-therapy, but this framing unintentionally pushed against the point I wanted to make) Some commenters on the previous article understood this point, but challenged its weight. It’s very cool, they said, to know how many neurons are in which brain lobe, but the main way that Psychology affected their lives was through bad clickbait studies used to buttress dumb policies; some p = 0.049 study says that exposure to microaggressions makes minorities’ brains shrivel into raisins, and now their company has to implement punitive DEI or be sued for hazardous work conditions. I won’t dispute this as an accurate description of how the sausage gets made, but it’s worth examining the trains of thought that connect this observation to a campaign against psychology in general: The dumb woke psychology was wrong and bad, and I don’t have good heuristics for distinguishing dumb woke psychology from other psychology, so I’m going to assume it’s all wrong and bad. The dumb woke psychology was wrong and bad; it seems useful to punish/discredit psychology as a whole to assist my campaign against it, so for propaganda purposes I will try to discredit psychology as a whole. To people in the first camp, my response is: come on, your heuristics aren’t that bad. “Microaggressions makes minorities’ brains shrivel up like raisins” is in the woke category; “the hippocampal theta rhythm seems to be associated with both memory and pathfinding, suggesting an unexpected yet surprisingly compelling relationship between the two” is in the not-woke category, don’t play dumb here. To people in the second camp, my response is: deliberately exaggerated propaganda campaigns are bad and this is a confession, not an excuse. Inability to view science through anything but a political lens was what got us into this problem; doubling down on it is a temporary solution but a recipe for permanent disaster. If you pronounce entire fields of science to be acceptable collateral damage in your campaign against bad political actors, you will alienate not just scientists but patients, clinicians, and general lovers of truth. Instead, you can say the thing you mean - that woke partisans shouldn’t try to occupy and exploit the otherwise-noble science of psychology for their own political gain - and wage the same campaign with a halo rather than a comic-book-villain goatee. From the font of oracular wisdom that is Weird Sun Twitter: [ Vessel Of Spirit@VesselOfSpirit i love you all conditionally but i love the good part of you unconditionally. even if it becomes a very small part 2:11 AM · Jan 22, 2015 1 Reply · 5 Reposts · 29 Likes ](https://x.com/VesselOfSpirit/status/558084551772471298) This is how I feel about psychology1, too, but with a touch more optimism. The good part of psychology is enormous, a hoard of endless treasures. You just have to look past the headlines! 1 To play devil’s advocate - should one always be so magnamious? Astrology? Phrenology? These seem different in that their entire orientation was flawed from the start; they didn’t simply fail to find the correct constellation-personality connections, the whole project of searching for connections between constellations and personality was doomed from the start. More difficult might be asking the same question about education research, which is notoriously bad. I don’t know enough about education research to know if there’s some settled science of correct and enlightening results lurking in the background beyond the day-to-day froth of poorly-conducted and politically-motivated studies. I think if it’s 90% bad, 10% good, it’s correct to call it bad as a compact way of communicating a useful truth; I think psychology is better than that, but admit it’s a tough judgment call.
Maryland’s youth turning over a new leaf? Survey shows positive trends.
Children used less alcohol and drugs in 2024 and reported less depression in the Maryland Department of Health’s 2024-2025 youth risk behavior survey.
UT San Antonio scientist highlights growing threat of antifungal resistance
For decades, scientists have studied antibiotic resistance, which is how bacteria evolve mechanisms to evade lifesaving drugs. Now, researchers are warning that a similar challenge is emerging among fungi, where resistance to frontline antifungal medications is making serious infections increasingly difficult to treat. Nathan Wiederhold, PharmD, director of the Fungus Testing Laboratory and professor […]
IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Registrational OptimUM-02 trial of the darovasertib combination in metastatic uveal melanoma (mUM) met its primary endpoint; new drug application (NDA) filing...
A common sugar may help cancer cells break free and spread
Chemotherapy-surviving ovarian cancer cells may release fructose to help neighboring tumor cells loosen, escape, and spread. The discovery suggests that sugary diets and cholesterol-lowering drugs could influence cancer progression, though the effects have not yet been confirmed in patients.
Cuyahoga County Sheriff’s Department Narcotics Unit puts drug organization out of business
Two men are under arrest after a two-month-long investigation by the Cuyahoga County Sheriff’s Department for selling large amounts of drugs across the city of Cleveland and throughout Cuyahoga County.
UT San Antonio scientist highlights growing threat of antifungal resistance
For decades, scientists have studied antibiotic resistance, which is how bacteria evolve mechanisms to evade lifesaving drugs. Now, researchers are warning that a similar challenge is emerging among fungi, where resistance to frontline antifungal medications is making serious infections increasingly difficult to treat. Nathan Wiederhold, PharmD, director of the Fungus Testing Laboratory and professor […]
Intermountain Health introduces new pancreatic cancer drug in western Colorado
Cancer center offering first-in-class treatment shown to more than double patients' expected length of life
For GLP-1 users, the in-store clothes shopping trip is back
Nora Nye, 58, is refreshing her wardrobe as she sizes down for the first time in over three decades after losing 80 pounds on weight-loss drug Mounjaro. Earlier this year, the Denver bankruptcy lawyer walked into a Macy's and found herself overwhelmed.
Tim Steller’s column: Grant Road businesses fold as construction adds to woes
For Star subscribers: The reconstruction of Grant Road is helping kill off Tucson businesses already weakened by street drug addiction and the sumer doldrums.
Scientists may have found a way to prevent statin muscle pain
Scientists have identified an immune response that may explain why statins cause muscle pain, weakness, and exercise intolerance in some people. The finding could eventually lead to treatments that protect muscles while preserving the drugs’ lifesaving cardiovascular benefits.
Editorial: Pennsylvania health insurance rates need triage
The cost of staying healthy is climbing. The cost of getting sick is even worse. Prescription drug costs are up. So is the amount of money people spend in urgent care — and that’s affordable compared with an emergency room visit. Testing, diagnostics, office visits, the little extras you don’t
Why alcohol and drug use may be declining among young Americans
New federal data shows that alcohol, cigarette and some drug use is declining among American youth and young adults. Public health specialists explain why.
Diabetes Drug Used For More Than 60 Years Found to Unexpectedly Affect The Brain
A hidden pathway is emerging.
He bought a fitness supplement online to bulk up, but ended up losing his mind
Daniel Murphy's mental health spiralled after he took missold drugs which had been mixed with steroids.
FDA clears autoinjector drug for home treatment of heart failure edema
A new drug delivery system may help reduce heart failure hospitalizations and related healthcare costs, which are expected to reach $70 billion by 2030.
Amgen discloses data breach, says patient information was stolen
Drugmaker Amgen said on Friday hackers stole company data and patient health information in a cybersecurity breach involving cloud storage systems run by third-party providers.
How scientists are trying to repair the body from within: Regenerative medicine and anti-aging
At Scripps Research and its drug discovery arm, the Calibr-Skaggs Institute for Innovative Medicines, scientists are developing regenerative medicine therapies designed to help the body repair itself from within. Unlike traditional medicines that primarily manage symptoms or slow disease progression, regenerative medicine aims to restore damaged tissues and rebuild function lost to aging and disease. Researchers are advancing programs focused on the heart, lungs, digestive tract and eyes, including investigational therapies for heart failure, idiopathic pulmonary fibrosis, inflammatory bowel disease, age-related macular degeneration and other chronic conditions that become more common as we age. Learn how scientists are activating the body’s natural repair mechanisms to explore a future where medicine may not only treat disease, but help reverse its damage.
Innovation Politics at the FDA - Petrie-Flom Center
The relationship between innovation and the Food and Drug Administration (FDA) has become a central topic of concern for a whole host of parties: academics, members of the National Academies of Sciences, Engineering, and Medicine, and several former FDA commissioners.
Maine GOP candidate outlines plan to fight drug addiction
Following a tour of Phoenix House in Lewiston, Charles said he would put in place more services to help those struggling with addiction, particularly in the immediate aftermath of the administration of Narcan, which reverses overdoses.
FDA advisers support easing restrictions on six peptides. Here’s what those drugs are and what happens next
Peptides have become one of the hottest trends in wellness, with promises like faster muscle recovery and healthier aging. And six of these compounds cleared a major hurdle last week, when an advisory panel to the US Food and Drug Administration voted in favor of making them available through compounding pharmacies.
CMS announces end to Medicare Part D prescription drug subsidies
With the change, premiums are expected to rise. However, the Centers for Medicare & Medicaid Services confirmed they cannot inflate by more than 6%, as capped by the Inflation Reduction Act.
Harvard Business School announces 2026-2027 Blavatnik Fellows
Harvard Business School (HBS) has named its 2026-27 Blavatnik Fellows. The fellowship offers HBS alumni and Harvard-affiliated postdoctoral researchers the opportunity to advance new life science technology ventures and develop their leadership talents during a 12-month fellowship year. To date, Blavatnik Fellows have founded 50 biomedical companies developing innovations including gene writing technologies, engineered cell therapies, oral biologic drug delivery platforms, AI-enabled digital health solutions, and therapeutics for cancer, neurological, and metabolic diseases. Collectively, Fellows have raised more than $800 million in private and public capital to advance their ventures.
The new "science golden age" looks suspiciously like a grift
This edition of PN is made possible by paid subscribers. Become one ⬇️ 🚀 Subscribe to PN 🚀 The Trump regime is trying to usher in a “Golden Age in Science” where scientific research is run like a Trump family business, artificial intelligence is all that matters, profit is everything, and expertise is for chumps. Or at least that’s the vision emerging from a new 123-page “Report to the President” from Michael Kratsios, the Director of the White House Office of Science and Technology Policy. In a normal administration, you could probably skip over learning about a science policy document — but this is no normal administration, and this is no normal science policy document. Instead, it’s Trump’s attempt to end the actual golden age of science that was kicked off in 1945 with the publication of '“The Endless Frontier” by Vannevar Bush. [ ](https://www.publicnotice.co/p/harmeet-dhillon-portland) [ Harmeet Dhillon demonstrates danger of posting through it ](https://www.publicnotice.co/p/harmeet-dhillon-portland) Liz Dye · Jul 29 [ Read full story ](https://www.publicnotice.co/p/harmeet-dhillon-portland) Bush, at President Franklin Delano Roosevelt’s request, laid out a vision of federal support for science that centered on funding universities to do basic research, saying that as long as those institutions were “vigorous and healthy and their scientists are free to pursue the truth wherever it may lead, there will be a flow of new scientific knowledge to those who can apply it to practical problems in Government, in industry, or elsewhere.” Kratsios’s report is supposed to be the successor to Bush’s, and even apes the format, but this isn’t really a document about science policy. It’s one about ending science research as we know it in favor of shoveling cash at big tech companies. While it might be temping to wave this away as an aspirational policy document, Trump has already begun to shift billions in research funds to AI projects and has taken a hatchet to science funding across the board. He’s teed up the shift Kratsios proposes here, and since neither Congress nor the Supreme Court seem inclined to stop him from doing whatever he wants with taxpayer money, it isn’t doomering or hyperbole to say we are staring down the barrel of a world where the only “science” the government intends to support is for-profit tech and defense advancements. Science for dummies Part of how you can tell this isn’t a document about science is that you are immediately faced with an absolute wall of business-speak of the worst sort. Did you know we must “tightly couple our science and technology enterprises to ensure that groundbreaking ideas invented in the United States are rapidly prototyped, tested, manufactured, and scaled domestically”? You do now! That tone isn’t surprising, because Kratsios has no background in science or research. He has a bachelor’s in political science and spent most of his career working for Peter Thiel at Thiel Capital. After a stint in the first Trump administration as Chief Technology Officer, where he also did not do any science, Kratsios was tasked in 2020 with overseeing the Pentagon’s research budget for a brief time, a position that, as the Wall Street Journal put it, “carries a great deal of power in terms of dictating investment allocations.” He spent the Biden years at Scale AI as “head of strategy,” which you will also note is neither a science nor a research job. But Scale AI has contracts with the Department of Defense and, as the Washington Post wrote in 2023, “has been aggressively pitching itself as the company that will help the US military in its existential battle with China.” And now you have the necessary background for our new golden age, which is going to be a golden age of taking money away from scientists and universities and giving it to companies like Scale AI. A note from Aaron: Working with brilliant contributors like Lisa takes resources. If you aren’t already a paid subscriber, please become one to support our work. 👇 Subscribe In a genuinely galling move, Katsios spends a lot of time slamming universities because of “administrative burdens on researchers” and the “well-documented inefficiencies” in academia, the message being that those damn universities waste the time of amazing researchers with paperwork. Except it’s the administration that is attempting to impose inefficient, unnecessary burdens on those researchers with a proposed Office of Management and Budget rule that would require senior political appointees to approve every science grant and ensure it aligns with Trump’s personal priorities. Researchers would also have to seek prior government approval to attend conferences or publicize their research. And political appointees could terminate any grant at any time if they feel like it. [ ](https://www.publicnotice.co/p/omb-rule-science-funding) [ The murder of expertise ](https://www.publicnotice.co/p/omb-rule-science-funding) Lisa Needham · Jun 11 [ Read full story ](https://www.publicnotice.co/p/omb-rule-science-funding) But when it comes to AI, we’re going to “restore permissionless innovation.” The report proposes to give lucky ducky innovators a pile of cash up front for grants lasting five years or longer, saying “awards should be fully-funded in year one, with all resources earmarked upfront, to minimize administrative burdens and reduce pressure for researchers to generate intermediate results to secure continued funding.” Yeah, wouldn’t want to have to make the Very Special Tech Bros show results or get money parceled out year by year like the plebes at universities. The report also proposes that we should have “fast grants” with “simplified applications requiring just a few pages of writing” because that is definitely how science works, just writing a bit off the dome and getting some cash. [ ](https://www.publicnotice.co/p/trump-ai-action-plan-altman-llms) [ Tech elites are turning AI into ChatGPTrump ](https://www.publicnotice.co/p/trump-ai-action-plan-altman-llms) Paul Waldman · July 29, 2025 [ Read full story ](https://www.publicnotice.co/p/trump-ai-action-plan-altman-llms) Oh, and we should have prizes and challenges, where multiple teams compete. The proposed prizes include incentives like “advance procurement commitments,” which means the federal government agrees to buy whatever is being developed. There’s also “regulatory fast-tracking,” making sure all those great AI thingies don’t have to wait too long to be unleashed on a market. These aren’t incentives to do science. These are incentives to develop things with tax dollars that you can then sell to the government for more tax dollars. In the suggestion that might be the most unhinged, the most very opposite of how both government and research work, our new age will include “golden tickets.” That’s where an individual reviewer in an agency — yes, just one person — can “recommend unconventional proposals that may not pass consensus-driven review panels” because somehow this will “surface valuable ideas too divisive for committees and attract higher quality reviewers by empowering them to exercise independent scientific judgment.” Yes, that’s saying that a random person in an agency should be able to shovel money at some idea even if it can’t pass a review panel, and that the opportunity to do so will attract better employees because apparently all the best minds in science are chomping at the bit to be allowed to unilaterally fund AI research based on their personal vibes. But that isn’t at all how actual science works, and actual scientists aren’t unhappy about review panels. They work collaboratively, not siloed in some secret race to create the next AI chatbot. A 2020 study by the National Bureau of Economic Research examined whether peer review panels succeed in helping agencies predict which research ideas will best advance science. Peer review was better at finding “diamond in the rough” applicants than a single government program official. How about that. Trump always wants a taste It’s painfully clear that what Katsios is trying to do here is turn the whole of government science research and funding into the sort of “move fast and break things” paradigm that is the hallmark of big tech. That method works to line the pockets of tech executives, but it isn’t science. There’s a reason the government funds different kinds of research than private tech companies do. What Katsios either fails to understand or deliberately ignores is that the federal government is the main funder of basic research precisely because it can take a long time for it to bear fruit and is not intended to be profitable as such. “Basic” here does not mean rudimentary or simple, but rather research that is designed to advance scientific knowledge instead of achieving a specific outcome or product. Big tech companies don’t widely fund that sort of research, because it doesn’t make them money. Industry dollars account for only about 20 percent of basic research funding, while the government contributes around 60 percent. Big tech companies and startups do, however, rely on and benefit from that basic research. A 2019 study found that 35 percent of all patents obtained by venture-backed startups from 1976 to 2016 cited federally supported research. Basic research funded by the NIH contributed to every single drug the FDA approved from 2010 to 2016. [ ](https://www.publicnotice.co/p/trump-saudi-nuclear-deal) [ The Saudi nuclear farce and governance by whim and meme ](https://www.publicnotice.co/p/trump-saudi-nuclear-deal) Noah Berlatsky · Jul 27 [ Read full story ](https://www.publicnotice.co/p/trump-saudi-nuclear-deal) Unlike inventing the next ChatGPT, actual science is slow and iterative. Government funding of research that, on its face, would not appear to lead to any big new invention is actually what underpins those big new inventions. If the government hadn’t funded research into desert lizard venom, we wouldn’t know about semaglutide, and we wouldn’t have Ozempic. If research scientists hadn’t studied how bees optimize nectar foraging within a colony, we wouldn’t have the algorithm that assigns internet traffic across computer servers. The report assiduously ignores that a symbiotic, profitable relationship between the federal government, universities, and private companies already exists. Each federal research dollar generates about $1.50 to $3.00 in long-term economic benefits. The $36 billion the government awarded in NIH research funding in fiscal year 2025 generated $94 billion in new economic activity. Trump’s proposed new golden age is intended to strip those billions from universities, resulting in the dismantling of departments and the shuttering of labs. But Katsios has a plan for that: Universities should just become trade schools to churn out no-show STEM degrees! “Require universities and community colleges to embed practical technical training and externships into STEM curricula. Let hands-on experience and industry credentials count toward degrees.” It’s quite the feat to, on the one hand, strip schools of funding for scientific research while simultaneously demanding to control what is taught and, oh, also, colleges need to give degrees to employees at big tech companies just for being employees at big tech companies. The new golden age would also exacerbate the brain drain Trump’s policies have already caused. Nature found that in the first quarter of 2025, US scientists submitted 32 percent more job applications abroad than in 2024. A March 2025 poll by Nature of roughly 1,600 scientists found that over 1,200 said they were considering leaving the country. Europe is investing $565 million to make it a “magnet for researchers” and provide funding for scientists who relocate. The new golden age is also about embedding Trump’s xenophobia into the fabric of American science. The report complains of an “over-reliance on foreign students” that “creates a security challenge our institutions are ill-equipped to address” and that a “reliance on foreign talent sidelines American students.” This is, to put it mildly, nonsense. International students pay far higher tuition and often receive no financial aid. Their tuition dollars are what make it possible for American students to get financial aid. In the 2023-2024 school year alone, international students contributed $43.8 billion to the US economy and supported over 378,000 jobs. Those 1.1 million international students accounted for only six percent of the total number of students in higher education that year, but were such an economic engine that for every three international students, one job was created or supported. It’s impossible not to wonder whether part of Trump’s loathing for universities and their leading role in scientific research is that there is no way for him to corrupt the process and make money off it in the same way he can by giving millions and billions to Silicon Valley types who, in turn, give him millions in cash. There’s no way for his children to invest in universities that the government then gives no-bid contracts to, fattening the family’s bottom line, which is pretty much the Trump sons’ current venture capital practice. Trump and Katsios’s view of science is narrow, cramped, and wrong. We’re not in a crisis, we’re not a failed state. We’ve been a science superpower for decades, and the only thing that threatens that is Donald Trump. Tech bros are already living high off the hog in this administration. They don’t need any more of our tax dollars. Hopefully this new golden age never comes to pass. Thanks for reading Public Notice. This post is public so feel free to share it. Share We’ll be back with more tomorrow. If you appreciate today’s PN, please do your part to keep us free by signing up for a paid subscription. 🚀 Subscribe to PN 🚀 Thanks for reading, and for your support.
Proposals to lower health costs get broad support in battlegrounds
Voters in battleground states and congressional districts tend to voice support for proposals in Congress that would expand access to health care or lower drug costs — often irrespective of their party affiliation — according to new polling from the University of Maryland. The poll, first shared with CQ Roll Call, surveyed people in 11 competitive states like Pennsylvania, Georgia […]
Cigna raises annual profit forecast on strength in health services unit
Cigna on Thursday raised its annual profit forecast, after beating quarterly earnings estimates on growth in its pharmacy and specialty drug businesses.
Florida urges doctors not to prescribe mental health medication for children
Florida's surgeon general has warned doctors not to prescribe antidepressants and other psych drugs for children, instead urging comprehensive evaluations and behavioral therapy as first line treatment options.
Trump administration to end Medicare Part D subsidy program in 2027
The prescription drug benefit is used by millions of seniors.
Biogen Beats Estimates as New Medicines Overtake MS Business
Biogen Inc. reported quarterly revenue and adjusted earnings that beat analysts’ expectations as sales of newly acquired kidney and eye-disease drugs helped offset declining revenue from multiple sclerosis medicines.
The Trump administration is halting a Medicare drug subsidy. Will premiums rise?
A temporary subsidy that reduced monthly premiums will end, and insurance companies are examining the impact.
CASPR Ends Tenagrity Contract as Agenda Turns to Gambling
Center for Addiction Science terminates Tenagrity Solutions lobbying contract focused on GLP-1 drug access. Read the latest policy update.
Florida's new child mental health guidance aligns with RFK Jr.'s push to curb psychiatric drug use
The state's new guidelines echo the Make America Healthy Again movement's call to reduce psychiatric medication use in children.
An entirely new kind of drug will help us treat the untreatable
The first of a new generation of drugs that works in a completely different way to existing ones has been approved. Columnist Michael Le Page says this approach could transform treatments for all kinds of conditions
National Survey on Drug Use and Health shows promising trends for youth mental health and drug use
A key U.S. government report on mental health, substance use and addiction shows continued improvements in several metrics, especially among young people
Federal survey shows promising trends for youth mental health and drug use
A key U.S. government report on mental health, substance use and addiction shows continued improvements in several metrics, especially among young people.
Federal survey shows promising trends for youth mental health and drug use
A key U.S. government report on mental health, substance use and addiction shows continued improvements in several metrics, especially among young people
Federal survey shows promising trends for youth mental health and drug use
A key U.S. government report on mental health, substance use and addiction shows continued improvements in several metrics, especially among young people
Antibiotic recalled after cardboard particles found in solution
Patients given the drug in question could face an increased risk of blood vessel blockages or inflammation.
Biodegradable implant can deliver targeted cancer immunotherapy while protecting healthy tissue
Scientists at Houston Methodist Research Institute have developed a biodegradable implant designed to deliver cancer-fighting immunotherapy drugs directly into tumors over an extended period, a strategy ...
National Survey on Drug Use, Mental Health
RDML. Christopher Jones, SAMHSA Acting Director, joins the show to talk about the recent SAMHSA survey.
Peptides are the latest wellness trend – but do they work?
A drug advisory committee in the US has recommended approval for several experimental peptides. But there have been no large-scale tests of these new compounds in humans, finds columnist Grace Wade
Pharma’s drug spending deflection
Job lock, surging prescription drug costs, No Surprises Act update, and more from STAT's Health Care Inc.
Drug-Resistant Superbugs May Be Jumping Between Pets And Humans, Scientists Warn
Livestock aren't the only issue.
High drug prices anger the public. Steep hospital costs elicit yawns. Why is that?
How is it that pharma companies—and, by extension, health insurers that cover drugs—have targets on their backs while hospitals live like wallflowers?
Some people are getting shut out when it comes to GLP-1 drugs. Here’s why.
People with obesity in the United States are being sorted between haves and have-nots.
‘Ozempic face’ and hair loss: what evidence is there for weight-loss drug side-effects?
Research into GLP-1 medications is not always robust but complaints such as digestive problems are well known
Oral GLP-1 drugs may quiet the brain’s food craving circuit
Newer oral drugs related to semaglutide medications such as Ozempic reduced pleasure-driven eating in mice by quieting a deep brain reward circuit. The finding could open new avenues for understanding food cravings and potentially treating substance use disorder.
ACC shares updated recommendations for managing HFpEF
A team of specialists detailed new data and recent breakthroughs in the diagnosis, management and treatment of heart failure with preserved ejection fraction.
FDA panel votes to loosen restrictions for controversial peptides
The vote marks a win for Health Secretary Robert F Kennedy who has said he's a big fan of the drugs, which haven't been well studied for human use.
U.S. health officials investigate new outbreak of parasite cyclospora
The Food and Drug Administration has not yet identified which products are linked to the illnesses.
Barren woman arrested, accused of selling marijuana at her business
A Barren County woman was arrested Wednesday on suspicion of illegally selling marijuana from her business. Agents with the Barren River Drug Task Force and inspectors with the Kentucky Department […]
Harvard Pilgrim, Tufts Health Plan CEO talks GLP-1 weigh-loss drug coverage
A year in, Point32Health CEO sits down to discuss insurance premiums, drug prices, and layoffs.
Federal government to spend $5B on AI-powered health, infrastructure research
More than 15 federal agencies will use AI to investigate the root causes of chronic diseases, develop treatments for pediatric cancer, expedite the discovery of prescription drugs and enhance U.S. energy infrastructure, among other related…
RELEASE: Gottheimer Hosts Telephone Town Hall to Discuss Health Care Costs, Medicare, Social Security, Utility Prices, Affordability in Jersey
Above: Gottheimer conducts a Telephone Town Hall with North Jersey families. WASHINGTON, D.C. — Last night, July 22, 2026, U.S. Congressman Josh Gottheimer (NJ-5) hosted a Telephone Town Hall with thousands of North Jersey residents to discuss his bipartisan efforts to lower health care and prescription drug costs, protect Social Security and Medicare, cut taxes, lower […]
Common Weight Loss Drugs Have Been Linked to a Higher Risk of Hair Loss
Here are the stats.
Officials: Barren County business owner arrested, charged with trafficking drugs out of storefront
Law enforcement agencies served a search warrant that led to a drug trafficking arrest.
Why aren’t health insurers rushing to cover GLP-1 prescriptions for beneficial weight loss?
In theory, GLP-1 receptor agonist drugs like semaglutide and tirzepatide should save a lot of money for the health insurers that pay for them. As it turns out, the lived reality is not keeping pace with the idealistic expectation.
FDA sees early promise in new gene therapy for BAG3-associated DCM
An investigational drug therapy from Affinia Therapeutics has secured the FDA's orphan drug designation. This means the company now has access to certain benefits, including tax credits and fee exemptions, as it works toward approval.
Biotech experts want FDA drug reviews based on science, not politics
Biotech experts call for the FDA to prioritize scientific expertise over political influence in drug reviews amid recent leadership changes and staffing challenges.
Health Committee advances Collins’ insulin price cap over GOP objections - Live Updates
The bill would limit the private insurance price for the diabetes drug to $35. Its approval by the GOP-led panel was highly unusual.
Samsung Biologics: geographic diversification is a sound business decision
Samsung Biologics has been on a steep upward growth trajectory since receiving its first licence to produce biologic drug substances in 2015.
Wyss Institute receives Massachusetts Life Science Center award to advance metabolomics and lipidomics research across Massachusetts ecosystem
By Benjamin Boettner (BOSTON) — The Wyss Institute at Harvard University has received an award from the Massachusetts Life Science Center (MLSC), enabling it to host a next-generation metabolomics and lipidomics analytical platform. The platform will allow its researchers to creatively pursue new approaches to biomarker and drug discovery across multiple health challenges the Institute...
US to spend $5 billion on health, construction research powered by AI
Agencies will use the funding to identify the root causes of chronic diseases, accelerate drug discovery, develop longer-lasting building materials.
NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS
/PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying...
Large Sterling Heights police operation swarms SW Detroit business
Also at the scene was the Drug Enforcement Agency, K-9 police units and officers wearing tactical fatigues and helmets.
Biotech experts want FDA drug reviews based on science, not politics
Biotech experts and industry executives are calling plans by the U.S. Food and Drug Administration — hit by job cuts last year — to hire thousands of employees and update clinical-trial standards encouraging, but want assurance that politics will not interfere in the agency's drug-review process.
Biotech experts want FDA drug reviews based on science, not politics
Biotech experts and industry executives are calling plans by the U.S. Food and Drug Administration — hit by job cuts last year — to hire thousands of employees and update clinical-trial standards encouraging, but want assurance that politics will not interfere in the agency's drug-review process.